Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor inhibitor ZD1839

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2364-2372

  Zanchi, Chiara ^a   Zuco, Valentina ^a   Lanzi, Cinzia ^a   Supino, Rosanna ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3' (1 ADAMANTYL) 4' HYDROXYBIPHENYL 4 YL]ACRYLIC ACID; CASPASE 8; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN BAD; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RETINOID; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; STRESS;

ADAMANTANE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASPASE 8; CASPASES; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CINNAMATES; DNA DAMAGE; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; HUMANS; OVARIAN NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; VULVAR NEOPLASMS;

EID: 16844377625     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2495     Document Type: Article

References (38)

1. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet 2003;4:721-9.
2. Garattini E, Gianni M, Terao M. Retinoid related molecules an emerging class of apoptotic agents with promising therapeutic potential in oncology: pharmacological activity and mechanisms of action. Curr Pharm Des 2004;10:433-48.
3. Fontana JA, Rishi AK. Classical and novel retinoids: their targets in cancer therapy. Leukemia 2002;16:463-72.
4. Ortiz MA, Bayon Y, Lopez-Hernandez FJ, Piedrafita FJ. Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives. Drug Resist Updat 2002;5:162-75.
5. Holmes WF, Soprano DR, Soprano KJ. Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines. J Cell Physiol 2004;199:317-29.
6. Lotan R. Receptor-independent induction of apoptosis by synthetic retinoids. J Biol Regul Homeost Agents 2003;17:13-28.
7. Cincinelli R, Dallavalle S, Merlini L, et al. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J Med Chem 2003;46:909-12.
8. Zuco V, Zanchi C, Cassinelli G, et al. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid. Cell Death Differ 2004;11:280-9.
9. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002;192:1-15.
10. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
11. Koizumi F, Kanzawa F, Ueda Y, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004;108:464-72.
12. Xu J-M, Azzariti A, Montemuro S, Lu B, Colucci G, Paradiso A. Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol 2003;66:551-63.
13. Magnè N, Fischel J-L, Tisson C, et al. Molecular mechanisms underlying the interaction between ZD1839 ("Iressa") and cisplatin/5-fluorouracil. Br J Cancer 2003;89:585-92.
14. Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8:3250-8.
15. Drewinko B, Loo TL, Brown JA, Gottlieb JA, Freireich EJ. Combination chemotherapy in vitro with Adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combination on cultured human lymphoma cells. Cancer Biochem Biophys 1976;1:187-95.
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
17. Furuta T, Takemura H, Liao Z-Y, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003;278:20303-12.
18. Xiao G-H, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. PNAS 2001;98:247-52.
19. Modesti M, Kanaar R. DNA repair: spot(light)s on chromatin. Curr Biol 2001;11:229-32.
20. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194-8.
21. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22.
22. Nicholson KM, Anderson NG. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 2002;14:381-95.
23. Mendelson J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
24. Levitzki A. EGF receptor as a therapeutic target. Lung Cancer 2003;41:9-14.
25. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCCI and ERCCI in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003;159:439-52.
26. Gilmore AP, Valentijn AJ, Wang P, et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 2002;277:27643-50.
27. Farhana L, Dawson MI, Huang Y, et al. Apoptosis signaling by the novel compound 3-C1-AHPC involves increased EGFR proteolysis and accompanying decreased phosphatidylinositol 3-kinase and AKT kinase activities. Oncogene 2004;23:1874-84.
28. Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 2004;198:410-21.
29. Hu Y, Bally M, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2003;2:641-9.
30. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000;79:355-69.
31. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-57.
32. Altieri DC. Validating survivin as a cancer therapeutic target. Nature 2003;3:46-54.
33. Pennati M, Binda M, Colella G, et al. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 2004;23:386-94.
34. Wu GS, Kim K, el-Deiry WS. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 2000;465:143-51.
35. Sun S-Y, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000;60:7149-55.
36. Grünwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment J Natl Cancer Inst 2003;95:851-67.
37. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
38. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.